Yew Bio-Pharm Group, Inc.
YEWB · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Revenue | $27 | $28 | $38 | $41 |
| % Growth | -2.1% | -25.8% | -7.3% | – |
| Cost of Goods Sold | $24 | $27 | $27 | $35 |
| Gross Profit | $4 | $1 | $11 | $5 |
| % Margin | 12.9% | 2.8% | 28.5% | 12.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $2 | $2 |
| SG&A Expenses | $1 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $2 | $2 |
| Operating Income | $3 | -$1 | $1 | $3 |
| % Margin | 9.4% | -2.2% | 1.9% | 8.2% |
| Other Income/Exp. Net | -$1 | -$0 | -$1 | -$0 |
| Pre-Tax Income | $1 | $1 | $0 | $3 |
| Tax Expense | $0 | $0 | $1 | $0 |
| Net Income | $1 | $1 | -$1 | $3 |
| % Margin | 5.4% | 3.5% | -3.5% | 7.9% |
| EPS | 0.03 | 0.02 | -0.025 | 0.06 |
| % Growth | 50% | 178.7% | -142.3% | – |
| EPS Diluted | 0.03 | 0.02 | -0.025 | 0.06 |
| Weighted Avg Shares Out | 52 | 52 | 52 | 52 |
| Weighted Avg Shares Out Dil | 52 | 52 | 52 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $2 | $11 | $4 |
| EBITDA | $5 | $1 | $20 | $3 |
| % Margin | 17.5% | 4.3% | 52.6% | 8.2% |